Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet

References

• Services CfMM. 42 CFR Parts 410, 413, and 414 Medicare Program; End-Stage Renal Disease Prospective Payment System; Final Rule and Proposed Rule: Centers for Medicare & Medicaid Services; Federal Register. August 12, 2010
   Google Scholar
• Watnick S, Weiner DE, Shaffer R, et al. Comparing mandated health care reforms: The Affordable Care Act, Accountable Care Organizations, and the Medicare ESRD Program. Clin J Am Soc Nephrol 2012;7:1535-43
   Google Scholar
• Fishbane S, Miller I, Wagner JD, et al. Changes to the end-stage renal disease quality incentive program. Kidney Int 2012;81:1167-71
   Google Scholar
• Block GA, Zeig S, Sugihara J, et al. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Nephrol Dial Transplant 2008;23:2311-8
   Google Scholar
• Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2010;26:1948-55
   Google Scholar
• Frazao JM, Messa P, Mellotte GJ, et al. Cinacalcet reduces plasma intact parathyroid hormone, serum phosphate and calcium levels in patients with secondary hyperparathyroidism irrespective of its severity. Clin Nephrol 2011;76:233-43
   Google Scholar
• Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002;13:1017-24
   PubMed Web of Science ®Google Scholar
• Kilpatrick R, Gill K, Block GA. Exploring the relationship between temporal trends in PTH, P and Ca in HD patients. Am Soc Nephrol 2010. Abstract and Poster
   Google Scholar
• Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011;26:1368-76
   PubMed Web of Science ®Google Scholar
• Moe SM, Chertow GM, Coburn JW, et al. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 2005;67:760-71
   PubMed Web of Science ®Google Scholar
• Naves-Diaz M, Passlick-Deetjen J, Guinsburg A, et al. Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transplant 2011;26:1938-47
   PubMed Web of Science ®Google Scholar
• Slatopolsky E, Delmez JA. Pathogenesis of secondary hyperparathyroidism. Nephrol Dial Transplant 1996;11(3 Suppl):130-5
   Google Scholar
• Alem AM, Sherrard DJ, Gillen DL, et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:396-9
   PubMed Web of Science ®Google Scholar
• Jadoul M, Albert JM, Akiba T, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006;70:1358-66
   PubMed Web of Science ®Google Scholar
• Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60
   PubMed Web of Science ®Google Scholar
• Shi N, Foley K, Lenhart G, et al. Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 2009;45:1084-90
   PubMed Web of Science ®Google Scholar
• Stehman-Breen CO, Sherrard DJ, Alem AM, et al. Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 2000;58:2200-5
   PubMed Web of Science ®Google Scholar
• Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005;67:2295-304
   PubMed Web of Science ®Google Scholar
• Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study. J Am Soc Nephrol 2005;16:1788-93
   PubMed Web of Science ®Google Scholar
• Raggi P, Boulay A, Chasan-Taber S, et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002;39:695-701
   PubMed Web of Science ®Google Scholar
• Doan QV, Gleeson M, Kim J, et al. Economic burden of cardiovascular events and fractures among patients with end-stage renal disease. Curr Med Res Opin 2007;23:1561-9
   PubMed Web of Science ®Google Scholar
• Joy MS, Karagiannis PC, Peyerl FW. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment. J Manag Care Pharm Jun 2007;13:397-411
   PubMed Web of Science ®Google Scholar
• Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
   PubMed Web of Science ®Google Scholar
• Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008;3:1718-25
   PubMed Web of Science ®Google Scholar
• Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
   PubMed Web of Science ®Google Scholar
• Palmer SC, McGregor DO, Craig JC, et al. Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009;4:CD008175
   PubMed Web of Science ®Google Scholar
• Kilpatrick RD, Danese MD, Belozeroff V, et al. The association of vitamin D use with hypercalcemia and hyperphosphatemia in hemodialysis patients: a case-crossover study. Pharmacoepidemiol Drug Saf 2011;20:914-21
   PubMed Web of Science ®Google Scholar
• Feldman RL, Desmarais MP, Muller JS. Orals in the bundle: a policy framework. Clin J Am Soc Nephrol 2013;8:1043-7
   Google Scholar
• Drummond M. Methods for the economic evaluation of health care programmes. 3rd edn. Great Claredon St, Oxford: Oxford University Press, 2005
   Google Scholar
• Messa P, Macario F, Yaqoob M, et al. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008;3:36-45
   PubMed Web of Science ®Google Scholar
• Shireman TI, Almehmi A, Wetmore JB, et al. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Am J Kidney Dis 2010;56:1108-16
   Google Scholar
• Amgen Inc. Thousand Oaks, Ca. Sensipar(R) Package Insert
   Google Scholar
• Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health: J Int Soc Pharmacoecon Outcomes Res 2009;12:409-18
   PubMed Web of Science ®Google Scholar
• Boer R, Lalla AM, Belozeroff V. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012;15:509-20
   PubMedGoogle Scholar
• Narayan R, Perkins RM, Berbano EP, et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007;49:801-13
   PubMed Web of Science ®Google Scholar
• Plosker GL. Cinacalcet: a pharmacoeconomic review of its use in secondary hyperparathyroidism in end-stage renal disease. Pharmacoeconomics 2011;29:807-21
   Google Scholar
• Eandi M, Pradelli L, Iannazzo S, et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010;29:1041-54
   Google Scholar
• Moe SM, Drueke TB. The KDIGO guideline on dialysate calcium and patient outcomes: need for hard evidence. Kidney Int 2011;79:478; author reply 478-9
   Google Scholar